ROIV – Roivant Sciences Ltd
ROIV — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
5.89
Margin Of Safety %
Put/Call OI Ratio
0.39
EPS Next Q Diff
EPS Last/This Y
-1.07
EPS This/Next Y
-0.06
Price
36.33
Target Price
41.27
Analyst Recom
1.31
Performance Q
28.47
Upside
-126.6%
Beta
1.12
Ticker: ROIV
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | ROIV | 34.51 | 0.41 | 0.02 | 49802 |
| 2026-07-14 | ROIV | 34.92 | 0.41 | 4.52 | 49756 |
| 2026-07-15 | ROIV | 34.89 | 0.41 | 0.02 | 49922 |
| 2026-07-16 | ROIV | 33.93 | 0.41 | 0.00 | 50026 |
| 2026-07-17 | ROIV | 34.52 | 0.41 | 6.67 | 50040 |
| 2026-07-20 | ROIV | 34.06 | 0.37 | 0.50 | 46006 |
| 2026-07-21 | ROIV | 34.94 | 0.37 | 0.05 | 46002 |
| 2026-07-22 | ROIV | 34.91 | 0.37 | 6.25 | 46011 |
| 2026-07-23 | ROIV | 35.12 | 0.38 | 0.14 | 46447 |
| 2026-07-24 | ROIV | 35.03 | 0.38 | 4.63 | 46470 |
| 2026-07-27 | ROIV | 34.7 | 0.38 | 0.10 | 46485 |
| 2026-07-28 | ROIV | 33.82 | 0.38 | 0.31 | 46482 |
| 2026-07-29 | ROIV | 32.86 | 0.38 | 1.36 | 46493 |
| 2026-07-30 | ROIV | 34.53 | 0.39 | 0.41 | 46521 |
| 2026-07-31 | ROIV | 33.91 | 0.39 | 0.06 | 46575 |
| 2026-08-03 | ROIV | 33.32 | 0.39 | 0.00 | 46574 |
| 2026-08-04 | ROIV | 34.61 | 0.39 | 0.18 | 46584 |
| 2026-08-05 | ROIV | 34.59 | 0.39 | 0.75 | 46615 |
| 2026-08-06 | ROIV | 35.11 | 0.39 | 0.47 | 46630 |
| 2026-08-07 | ROIV | 36.32 | 0.39 | 0.11 | 47260 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | ROIV | 34.49 | -42.2 | - | -1.50 |
| 2026-07-14 | ROIV | 34.91 | -42.2 | - | -1.50 |
| 2026-07-15 | ROIV | 34.87 | -42.2 | - | -1.50 |
| 2026-07-16 | ROIV | 33.93 | -42.2 | - | -1.50 |
| 2026-07-17 | ROIV | 34.52 | -42.2 | - | -1.50 |
| 2026-07-20 | ROIV | 34.07 | -42.2 | - | -1.50 |
| 2026-07-21 | ROIV | 34.95 | -42.2 | - | -1.50 |
| 2026-07-22 | ROIV | 34.91 | -42.2 | - | -1.50 |
| 2026-07-23 | ROIV | 35.09 | -42.2 | - | -1.50 |
| 2026-07-24 | ROIV | 35.03 | -42.2 | - | -1.50 |
| 2026-07-27 | ROIV | 34.70 | -42.2 | - | -1.50 |
| 2026-07-28 | ROIV | 33.83 | -42.2 | - | -1.50 |
| 2026-07-29 | ROIV | 32.87 | -42.2 | - | -1.50 |
| 2026-07-30 | ROIV | 34.51 | -42.2 | - | -1.50 |
| 2026-07-31 | ROIV | 33.91 | -42.2 | - | -1.50 |
| 2026-08-03 | ROIV | 33.31 | -42.2 | - | -1.50 |
| 2026-08-04 | ROIV | 33.31 | -42.2 | - | -1.50 |
| 2026-08-05 | ROIV | 34.60 | -42.2 | - | -1.50 |
| 2026-08-06 | ROIV | 35.11 | -42.2 | - | -1.50 |
| 2026-08-07 | ROIV | 36.33 | -42.2 | - | -1.50 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | ROIV | -6.57 | 4.57 | 6.42 |
| 2026-07-14 | ROIV | -6.57 | 4.57 | 6.42 |
| 2026-07-15 | ROIV | -6.48 | 4.57 | 6.42 |
| 2026-07-16 | ROIV | -6.48 | 4.57 | 6.42 |
| 2026-07-17 | ROIV | -6.48 | 4.57 | 6.42 |
| 2026-07-20 | ROIV | -6.48 | 4.77 | 6.42 |
| 2026-07-21 | ROIV | -6.48 | 4.77 | 6.42 |
| 2026-07-22 | ROIV | -6.48 | 4.77 | 6.42 |
| 2026-07-23 | ROIV | -6.48 | 4.77 | 6.42 |
| 2026-07-24 | ROIV | -6.48 | 4.77 | 6.42 |
| 2026-07-27 | ROIV | -6.48 | 4.80 | 7.09 |
| 2026-07-28 | ROIV | -6.48 | 4.80 | 7.09 |
| 2026-07-29 | ROIV | -6.48 | 4.80 | 7.09 |
| 2026-07-30 | ROIV | -6.57 | 4.80 | 7.09 |
| 2026-07-31 | ROIV | -6.57 | 4.80 | 7.09 |
| 2026-08-03 | ROIV | -6.54 | 5.06 | 5.89 |
| 2026-08-04 | ROIV | -12.50 | 5.06 | 5.89 |
| 2026-08-05 | ROIV | -12.50 | 5.06 | 5.89 |
| 2026-08-06 | ROIV | -12.50 | 5.06 | 5.89 |
| 2026-08-07 | ROIV | -12.50 | 5.06 | 5.89 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.36
Avg. EPS Est. Next Quarter
-0.4
Insider Transactions
-12.5
Institutional Transactions
5.06
Beta
1.12
Average Sales Estimate Current Quarter
2
Average Sales Estimate Next Quarter
4
Fair Value
Quality Score
43
Growth Score
28
Sentiment Score
77
Actual DrawDown %
1.8
Max Drawdown 5-Year %
Target Price
41.27
P/E
Forward P/E
PEG
P/S
3485.39
P/B
6.2
P/Free Cash Flow
EPS
-0.44
Average EPS Est. Cur. Y
-1.5
EPS Next Y. (Est.)
-1.56
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-3534.96
Relative Volume
1.12
Return on Equity vs Sector %
-33.6
Return on Equity vs Industry %
-17.5
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.34
EBIT Estimation
◆
ROIV
Healthcare
$36.33
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
62.1
Range 1M
83.1%
Sup Dist
7.2%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
-150.6%
EPS NY
11.7%
52W%
97.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+13.6% upside
Upside
+13.6%
Quality
43
ROIV — P/E HistoricalBiotechnology
Roivant Sciences Ltd.Sector: Healthcare
Industry: Biotechnology
Employees: 721
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
ROIV
Latest News
—
Caricamento notizie per ROIV…
stock quote shares ROIV – Roivant Sciences Ltd Stock Price stock today
news today ROIV – Roivant Sciences Ltd stock forecast ,stock prediction 2023 2024 2025
marketwatch ROIV – Roivant Sciences Ltd yahoo finance google finance
stock history ROIV – Roivant Sciences Ltd invest stock market
stock prices ROIV premarket after hours
ticker ROIV fair value insiders trading